Company: HCWB
Filing Date: 2025-02-03
Form Type: 8-K
Source: 0000950170-25-012021
Chunk: 0

Company: HCW Biologics Inc.
Filing Date: 2025-02-03
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On February 3, 2025, HCW Biologics Inc. (the “ Company”) issued a press release announcing that the Company was cleared by the U. S. Food and Drug Administration to proceed to evaluate HCW9302, one of the Company’s lead product candidates, in a Phase 1 clinical trial in patients with moderate to severe alopecia areata. A copy of that press release is furnished as Exhibit 99.1 hereto.

The information furnished in this Current Report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.